{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:35:05Z","timestamp":1776990905712,"version":"3.51.4"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Institute of Health, United States","award":["R01AI182237"],"award-info":[{"award-number":["R01AI182237"]}]},{"DOI":"10.13039\/100014731","name":"Global Lyme Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016230","name":"Steven and Alexandra Cohen Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016230","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-42941-x","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T10:45:25Z","timestamp":1773398725000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of immunoreactive epitopes in the sera and cerebrospinal fluid of patients with post-treatment Lyme disease syndrome"],"prefix":"10.1038","volume":"16","author":[{"given":"Adriana R.","family":"Marques","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Sanchez-Vicente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akash","family":"Nagapurkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleah","family":"Eschman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siu Ping","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. Ian","family":"Lipkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafal","family":"Tokarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"42941_CR1","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.3201\/eid2708.204763","volume":"27","author":"AR Marques","year":"2021","unstructured":"Marques, A. R., Strle, F. & Wormser, G. P. Comparison of Lyme Disease in the United States and Europe. Emerg. Infect. Dis. 27, 2017\u20132024. https:\/\/doi.org\/10.3201\/eid2708.204763 (2021).","journal-title":"Emerg. Infect. Dis."},{"key":"42941_CR2","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.idc.2022.03.004","volume":"36","author":"P Mead","year":"2022","unstructured":"Mead, P. Epidemiology of Lyme Disease. Infect. Dis. Clin. North. Am. 36, 495\u2013521. https:\/\/doi.org\/10.1016\/j.idc.2022.03.004 (2022).","journal-title":"Infect. Dis. Clin. North. Am."},{"key":"42941_CR3","doi-asserted-by":"publisher","first-page":"616","DOI":"10.3201\/eid2702.202731","volume":"27","author":"KJ Kugeler","year":"2021","unstructured":"Kugeler, K. J., Schwartz, A. M., Delorey, M. J., Mead, P. S. & Hinckley, A. F. Estimating the frequency of Lyme Disease diagnoses, United States, 2010\u20132018. Emerg. Infect. Dis. 27, 616\u2013619. https:\/\/doi.org\/10.3201\/eid2702.202731 (2021).","journal-title":"Emerg. Infect. Dis."},{"key":"42941_CR4","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1086\/508667","volume":"43","author":"GP Wormser","year":"2006","unstructured":"Wormser, G. P. et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: Clinical practice guidelines by the Infectious Diseases Society of America. Clin. Infect. Dis. 43, 1089\u20131134. https:\/\/doi.org\/10.1086\/508667 (2006).","journal-title":"Clin. Infect. Dis."},{"key":"42941_CR5","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.idc.2022.04.004","volume":"36","author":"A Marques","year":"2022","unstructured":"Marques, A. Persistent symptoms after treatment of Lyme Disease. Infect. Dis. Clin. North. Am. 36, 621\u2013638. https:\/\/doi.org\/10.1016\/j.idc.2022.04.004 (2022).","journal-title":"Infect. Dis. Clin. North. Am."},{"key":"42941_CR6","doi-asserted-by":"publisher","first-page":"273","DOI":"10.7326\/0003-4819-117-4-273","volume":"117","author":"RB Nadelman","year":"1992","unstructured":"Nadelman, R. B. et al. Comparison of cefuroxime axetil and doxycycline in the treatment of early Lyme disease. Ann. Intern. Med. 117, 273\u2013280. https:\/\/doi.org\/10.7326\/0003-4819-117-4-273 (1992).","journal-title":"Ann. Intern. Med."},{"key":"42941_CR7","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/BF01710737","volume":"21","author":"F Strle","year":"1993","unstructured":"Strle, F. et al. Azithromycin versus doxycycline for treatment of erythema migrans: Clinical and microbiological findings. Infection 21, 83\u201388. https:\/\/doi.org\/10.1007\/BF01710737 (1993).","journal-title":"Infection"},{"key":"42941_CR8","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1128\/AAC.39.3.661","volume":"39","author":"SW Luger","year":"1995","unstructured":"Luger, S. W. et al. Comparison of cefuroxime axetil and doxycycline in treatment of patients with early Lyme disease associated with erythema migrans. Antimicrob. Agents Chemother. 39, 661\u2013667. https:\/\/doi.org\/10.1128\/AAC.39.3.661 (1995).","journal-title":"Antimicrob. Agents Chemother."},{"key":"42941_CR9","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1056\/NEJM199610243351703","volume":"335","author":"MA Gerber","year":"1996","unstructured":"Gerber, M. A., Shapiro, E. D., Burke, G. S., Parcells, V. J. & Bell, G. L. Lyme disease in children in southeastern Connecticut. Pediatric Lyme Disease Study Group. N. Engl. J. Med. 335, 1270\u20131274. https:\/\/doi.org\/10.1056\/NEJM199610243351703 (1996).","journal-title":"N. Engl. J. Med."},{"key":"42941_CR10","doi-asserted-by":"publisher","first-page":"785","DOI":"10.7326\/0003-4819-124-9-199605010-00002","volume":"124","author":"BJ Luft","year":"1996","unstructured":"Luft, B. J. et al. Azithromycin compared with amoxicillin in the treatment of erythema migrans. A double-blind, randomized, controlled trial. Ann. Intern. Med. 124, 785\u2013791. https:\/\/doi.org\/10.7326\/0003-4819-124-9-199605010-00002 (1996).","journal-title":"Ann. Intern. Med."},{"key":"42941_CR11","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1056\/NEJM199707313370501","volume":"337","author":"RJ Dattwyler","year":"1997","unstructured":"Dattwyler, R. J. et al. Ceftriaxone compared with doxycycline for the treatment of acute disseminated Lyme disease. N. Engl. J. Med. 337, 289\u2013294. https:\/\/doi.org\/10.1056\/NEJM199707313370501 (1997).","journal-title":"N. Engl. J. Med."},{"key":"42941_CR12","first-page":"916","volume":"111","author":"M Arnez","year":"1999","unstructured":"Arnez, M., Radsel-Medvescek, A., Pleterski-Rigler, D., Ruzic-Sabljic, E. & Strle, F. Comparison of cefuroxime axetil and phenoxymethyl penicillin for the treatment of children with solitary erythema migrans. Wien. Klin. Wochenschr. 111, 916\u2013922 (1999).","journal-title":"Wien. Klin. Wochenschr."},{"key":"42941_CR13","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s150100050069","volume":"28","author":"B Barsic","year":"2000","unstructured":"Barsic, B., Maretic, T., Majerus, L. & Strugar, J. Comparison of azithromycin and doxycycline in the treatment of erythema migrans. Infection 28, 153\u2013156. https:\/\/doi.org\/10.1007\/s150100050069 (2000).","journal-title":"Infection"},{"key":"42941_CR14","first-page":"498","volume":"114","author":"M Arnez","year":"2002","unstructured":"Arnez, M., Pleterski-Rigler, D., Luznik-Bufon, T., Ruzic-Sabljic, E. & Strle, F. Solitary erythema migrans in children: Comparison of treatment with azithromycin and phenoxymethylpenicillin. Wien. Klin. Wochenschr. 114, 498\u2013504 (2002).","journal-title":"Wien. Klin. Wochenschr."},{"key":"42941_CR15","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1542\/peds.109.6.1173","volume":"109","author":"SC Eppes","year":"2002","unstructured":"Eppes, S. C. & Childs, J. A. Comparative study of cefuroxime axetil versus amoxicillin in children with early Lyme disease. Pediatrics 109, 1173\u20131177. https:\/\/doi.org\/10.1542\/peds.109.6.1173 (2002).","journal-title":"Pediatrics"},{"key":"42941_CR16","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/s0002-9343(03)00308-5","volume":"115","author":"J Nowakowski","year":"2003","unstructured":"Nowakowski, J. et al. Long-term follow-up of patients with culture-confirmed Lyme disease. Am. J. Med. 115, 91\u201396. https:\/\/doi.org\/10.1016\/s0002-9343(03)00308-5 (2003).","journal-title":"Am. J. Med."},{"key":"42941_CR17","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.amjmed.2009.05.011","volume":"123","author":"D Cerar","year":"2010","unstructured":"Cerar, D., Cerar, T., Ruzic-Sabljic, E., Wormser, G. P. & Strle, F. Subjective symptoms after treatment of early Lyme disease. Am. J. Med. 123, 79\u201386. https:\/\/doi.org\/10.1016\/j.amjmed.2009.05.011 (2010).","journal-title":"Am. J. Med."},{"key":"42941_CR18","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1097\/INF.0000000000000804","volume":"34","author":"M Arnez","year":"2015","unstructured":"Arnez, M. & Ruzic-Sabljic, E. Azithromycin is equally effective as amoxicillin in children with solitary erythema migrans. Pediatr. Infect. Dis. J. 34, 1045\u20131048. https:\/\/doi.org\/10.1097\/INF.0000000000000804 (2015).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"42941_CR19","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/arclin\/acw098","volume":"32","author":"KT Bechtold","year":"2017","unstructured":"Bechtold, K. T., Rebman, A. W., Crowder, L. A., Johnson-Greene, D. & Aucott, J. N. Standardized symptom measurement of individuals with early Lyme disease over time. Arch. Clin. Neuropsychol. 32, 129\u2013141. https:\/\/doi.org\/10.1093\/arclin\/acw098 (2017).","journal-title":"Arch. Clin. Neuropsychol."},{"key":"42941_CR20","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1080\/02813432.2017.1288812","volume":"35","author":"KE Eliassen","year":"2017","unstructured":"Eliassen, K. E., Hjetland, R., Reiso, H., Lindbaek, M. & Tschudi-Madsen, H. Symptom load and general function among patients with erythema migrans: A prospective study with a 1-year follow-up after antibiotic treatment in Norwegian general practice. Scand. J. Prim. Health Care 35, 75\u201383. https:\/\/doi.org\/10.1080\/02813432.2017.1288812 (2017).","journal-title":"Scand. J. Prim. Health Care"},{"key":"42941_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/jcm7120506","author":"K Borsic","year":"2018","unstructured":"Borsic, K., Blagus, R., Cerar, T., Strle, F. & Stupica, D. Clinical course, serologic response, and long-term outcome in elderly patients with early Lyme Borreliosis. J. Clin. Med. https:\/\/doi.org\/10.3390\/jcm7120506 (2018).","journal-title":"J. Clin. Med."},{"key":"42941_CR22","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.ijid.2022.01.033","volume":"116","author":"JN Aucott","year":"2022","unstructured":"Aucott, J. N. et al. Risk of post-treatment Lyme disease in patients with ideally-treated early Lyme disease: A prospective cohort study. Int. J. Infect. Dis. 116, 230\u2013237. https:\/\/doi.org\/10.1016\/j.ijid.2022.01.033 (2022).","journal-title":"Int. J. Infect. Dis."},{"key":"42941_CR23","doi-asserted-by":"publisher","first-page":"421","DOI":"10.7326\/0003-4819-136-6-200203190-00005","volume":"136","author":"RP Smith","year":"2002","unstructured":"Smith, R. P. et al. Clinical characteristics and treatment outcome of early Lyme disease in patients with microbiologically confirmed erythema migrans. Ann. Intern. Med. 136, 421\u2013428. https:\/\/doi.org\/10.7326\/0003-4819-136-6-200203190-00005 (2002).","journal-title":"Ann. Intern. Med."},{"key":"42941_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0261194","volume":"16","author":"D Stupica","year":"2021","unstructured":"Stupica, D. et al. Association between statin use and clinical course, microbiologic characteristics, and long-term outcome of early Lyme borreliosis. A post hoc analysis of prospective clinical trials of adult patients with erythema migrans. PLoS One 16, e0261194. https:\/\/doi.org\/10.1371\/journal.pone.0261194 (2021).","journal-title":"PLoS One"},{"key":"42941_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0136600","volume":"10","author":"D Stupica","year":"2015","unstructured":"Stupica, D. et al. Correlation of culture positivity, PCR positivity, and burden of Borrelia burgdorferi sensu lato in skin samples of erythema migrans patients with clinical findings. PLoS One 10, e0136600. https:\/\/doi.org\/10.1371\/journal.pone.0136600 (2015).","journal-title":"PLoS One"},{"key":"42941_CR26","doi-asserted-by":"publisher","first-page":"697","DOI":"10.7326\/0003-4819-138-9-200305060-00005","volume":"138","author":"GP Wormser","year":"2003","unstructured":"Wormser, G. P. et al. Duration of antibiotic therapy for early Lyme disease. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 138, 697\u2013704. https:\/\/doi.org\/10.7326\/0003-4819-138-9-200305060-00005 (2003).","journal-title":"Ann. Intern. Med."},{"key":"42941_CR27","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1001\/jamadermatol.2018.2306","volume":"154","author":"D Stupica","year":"2018","unstructured":"Stupica, D. et al. Comparison of clinical course and treatment outcome for patients with early disseminated or early localized Lyme borreliosis. JAMA. Dermatol. 154, 1050\u20131056. https:\/\/doi.org\/10.1001\/jamadermatol.2018.2306 (2018).","journal-title":"JAMA. Dermatol."},{"key":"42941_CR28","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1093\/jac\/dkx534","volume":"73","author":"D Stupica","year":"2018","unstructured":"Stupica, D. et al. Oral doxycycline versus intravenous ceftriaxone for treatment of multiple erythema migrans: An open-label alternate-treatment observational trial. J. Antimicrob. Chemother. 73, 1352\u20131358. https:\/\/doi.org\/10.1093\/jac\/dkx534 (2018).","journal-title":"J. Antimicrob. Chemother."},{"key":"42941_CR29","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.1093\/cid\/ciz1215","volume":"71","author":"GP Wormser","year":"2020","unstructured":"Wormser, G. P. et al. Prospective evaluation of the frequency and severity of symptoms in Lyme disease patients with erythema migrans compared with matched controls at baseline, 6 months, and 12 months. Clin. Infect. Dis. 71, 3118\u20133124. https:\/\/doi.org\/10.1093\/cid\/ciz1215 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"42941_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2021.100142","volume":"6","author":"J Ursinus","year":"2021","unstructured":"Ursinus, J. et al. Prevalence of persistent symptoms after treatment for Lyme borreliosis: A prospective observational cohort study. Lancet. Reg. Health Eur. 6, 100142. https:\/\/doi.org\/10.1016\/j.lanepe.2021.100142 (2021).","journal-title":"Lancet. Reg. Health Eur."},{"key":"42941_CR31","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/S1473-3099(22)00528-X","volume":"23","author":"D Stupica","year":"2023","unstructured":"Stupica, D. et al. Treatment of erythema migrans with doxycycline for 7 days versus 14 days in Slovenia: A randomised open-label non-inferiority trial. Lancet. Infect. Dis. 23, 371\u2013379. https:\/\/doi.org\/10.1016\/S1473-3099(22)00528-X (2023).","journal-title":"Lancet. Infect. Dis."},{"key":"42941_CR32","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1093\/cid\/cis402","volume":"55","author":"D Stupica","year":"2012","unstructured":"Stupica, D., Lusa, L., Ruzic-Sabljic, E., Cerar, T. & Strle, F. Treatment of erythema migrans with doxycycline for 10 days versus 15 days. Clin. Infect. Dis. 55, 343\u2013350. https:\/\/doi.org\/10.1093\/cid\/cis402 (2012).","journal-title":"Clin. Infect. Dis."},{"key":"42941_CR33","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ado2103","volume":"16","author":"A Marques","year":"2024","unstructured":"Marques, A. Symptoms after Lyme disease: What\u2019s past is prologue. Sci. Transl. Med. 16, eado2103. https:\/\/doi.org\/10.1126\/scitranslmed.ado2103 (2024).","journal-title":"Sci. Transl. Med."},{"key":"42941_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-21349-2","volume":"8","author":"R Tokarz","year":"2018","unstructured":"Tokarz, R. et al. A multiplex serologic platform for diagnosis of tick-borne diseases. Sci. Rep. 8, 3158. https:\/\/doi.org\/10.1038\/s41598-018-21349-2 (2018).","journal-title":"Sci. Rep."},{"key":"42941_CR35","unstructured":"Centers for Disease Control and Prevention. Lyme Disease (Borrelia burgdorferi) 2017 Case Definition., (2017). https:\/\/ndc.services.cdc.gov\/case-definitions\/lyme-disease-2017\/"},{"key":"42941_CR36","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.02360-24","volume":"15","author":"R Tokarz","year":"2024","unstructured":"Tokarz, R. et al. Identification of reactive Borrelia burgdorferi peptides associated with Lyme disease. mBio 15, e0236024. https:\/\/doi.org\/10.1128\/mbio.02360-24 (2024).","journal-title":"mBio"},{"key":"42941_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ttbdis.2019.101314","volume":"11","author":"R Tokarz","year":"2020","unstructured":"Tokarz, R. et al. Identification of immunoreactive linear epitopes of Borrelia miyamotoi. Ticks. Tick. Borne. Dis. 11, 101314. https:\/\/doi.org\/10.1016\/j.ttbdis.2019.101314 (2020).","journal-title":"Ticks. Tick. Borne. Dis."},{"key":"42941_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ttbdis.2022.101999","volume":"13","author":"T Tagliafierro","year":"2022","unstructured":"Tagliafierro, T. et al. Detection of antibodies to Anaplasma phagocytophilum and Babesia microti using linear peptides. Ticks. Tick. Borne. Dis. 13, 101999. https:\/\/doi.org\/10.1016\/j.ttbdis.2022.101999 (2022).","journal-title":"Ticks. Tick. Borne. Dis."},{"key":"42941_CR39","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.clim.2011.06.005","volume":"141","author":"A Chandra","year":"2011","unstructured":"Chandra, A., Latov, N., Wormser, G. P., Marques, A. R. & Alaedini, A. Epitope mapping of antibodies to VlsE protein of Borrelia burgdorferi in post-Lyme disease syndrome. Clin. Immunol. 141, 103\u2013110. https:\/\/doi.org\/10.1016\/j.clim.2011.06.005 (2011).","journal-title":"Clin. Immunol."},{"key":"42941_CR40","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.00347-25","volume":"63","author":"N Nair","year":"2025","unstructured":"Nair, N., Marques, A., Horn, E. J., Brown, G. & Gomes-Solecki, M. Class and isotype of VlsE-specific antibody differentiates Lyme disease stage. J. Clin. Microbiol. 63, e0034725. https:\/\/doi.org\/10.1128\/jcm.00347-25 (2025).","journal-title":"J. Clin. Microbiol."},{"key":"42941_CR41","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1093\/cid\/cit735","volume":"58","author":"K Strle","year":"2014","unstructured":"Strle, K., Stupica, D., Drouin, E. E., Steere, A. C. & Strle, F. Elevated levels of IL-23 in a subset of patients with post-Lyme disease symptoms following erythema migrans. Clin. Infect. Dis. 58, 372\u2013380. https:\/\/doi.org\/10.1093\/cid\/cit735 (2014).","journal-title":"Clin. Infect. Dis."},{"key":"42941_CR42","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1128\/CVI.00002-11","volume":"18","author":"A Chandra","year":"2011","unstructured":"Chandra, A., Wormser, G. P., Marques, A. R., Latov, N. & Alaedini, A. Anti-Borrelia burgdorferi antibody profile in post-Lyme disease syndrome. Clin. Vaccine Immunol. 18, 767\u2013771. https:\/\/doi.org\/10.1128\/CVI.00002-11 (2011).","journal-title":"Clin. Vaccine Immunol."},{"key":"42941_CR43","doi-asserted-by":"publisher","DOI":"10.1128\/msphere.00252-22","volume":"7","author":"E Movahed","year":"2022","unstructured":"Movahed, E. et al. Serological analysis identifies consequential B cell epitopes on the flexible linker and C-terminus of decorin binding protein A (DbpA) from Borrelia burgdorferi. mSphere 7, e0025222. https:\/\/doi.org\/10.1128\/msphere.00252-22 (2022).","journal-title":"mSphere"},{"key":"42941_CR44","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1073\/pnas.0306845101","volume":"101","author":"D Grimm","year":"2004","unstructured":"Grimm, D. et al. Outer-surface protein C of the Lyme disease spirochete: a protein induced in ticks for infection of mammals. Proc Natl. Acad. Sci. U S A 101, 3142\u20133147. https:\/\/doi.org\/10.1073\/pnas.0306845101 (2004).","journal-title":"Proc Natl. Acad. Sci. U S A"},{"key":"42941_CR45","doi-asserted-by":"publisher","first-page":"3554","DOI":"10.1128\/IAI.01950-05","volume":"74","author":"K Tilly","year":"2006","unstructured":"Tilly, K. et al. Borrelia burgdorferi OspC protein required exclusively in a crucial early stage of mammalian infection. Infect. Immun. 74, 3554\u20133564. https:\/\/doi.org\/10.1128\/IAI.01950-05 (2006).","journal-title":"Infect. Immun."},{"key":"42941_CR46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0015830","volume":"5","author":"SV Seemanapalli","year":"2010","unstructured":"Seemanapalli, S. V., Xu, Q., McShan, K. & Liang, F. T. Outer surface protein C is a dissemination-facilitating factor of Borrelia burgdorferi during mammalian infection. PLoS One 5, e15830. https:\/\/doi.org\/10.1371\/journal.pone.0015830 (2010).","journal-title":"PLoS One"},{"key":"42941_CR47","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.1128\/IAI.67.7.3518-3524.1999","volume":"67","author":"G Seinost","year":"1999","unstructured":"Seinost, G. et al. Four clones of Borrelia burgdorferi sensu stricto cause invasive infection in humans. Infect. Immun. 67, 3518\u20133524. https:\/\/doi.org\/10.1128\/IAI.67.7.3518-3524.1999 (1999).","journal-title":"Infect. Immun."},{"key":"42941_CR48","doi-asserted-by":"publisher","first-page":"5059","DOI":"10.1128\/jcm.41.11.5059-5065.2003","volume":"41","author":"V Lagal","year":"2003","unstructured":"Lagal, V., Postic, D., Ruzic-Sabljic, E. & Baranton, G. Genetic diversity among Borrelia strains determined by single-strand conformation polymorphism analysis of the ospC gene and its association with invasiveness. J. Clin. Microbiol. 41, 5059\u20135065. https:\/\/doi.org\/10.1128\/jcm.41.11.5059-5065.2003 (2003).","journal-title":"J. Clin. Microbiol."},{"key":"42941_CR49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1011243","volume":"19","author":"JE Lemieux","year":"2023","unstructured":"Lemieux, J. E. et al. Whole genome sequencing of human Borrelia burgdorferi isolates reveals linked blocks of accessory genome elements located on plasmids and associated with human dissemination. PLoS Pathog. 19, e1011243. https:\/\/doi.org\/10.1371\/journal.ppat.1011243 (2023).","journal-title":"PLoS Pathog."},{"key":"42941_CR50","doi-asserted-by":"publisher","first-page":"4407","DOI":"10.1128\/JCM.01077-06","volume":"44","author":"KL Jones","year":"2006","unstructured":"Jones, K. L. et al. Borrelia burgdorferi genetic markers and disseminated disease in patients with early Lyme disease. J. Clin. Microbiol. 44, 4407\u20134413. https:\/\/doi.org\/10.1128\/JCM.01077-06 (2006).","journal-title":"J. Clin. Microbiol."},{"key":"42941_CR51","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1128\/JCM.43.4.1879-1884.2005","volume":"43","author":"MY Alghaferi","year":"2005","unstructured":"Alghaferi, M. Y. et al. Borrelia burgdorferi ospC heterogeneity among human and murine isolates from a defined region of northern Maryland and southern Pennsylvania: Lack of correlation with invasive and noninvasive genotypes. J. Clin. Microbiol. 43, 1879\u20131884. https:\/\/doi.org\/10.1128\/JCM.43.4.1879-1884.2005 (2005).","journal-title":"J. Clin. Microbiol."},{"key":"42941_CR52","doi-asserted-by":"publisher","first-page":"7869","DOI":"10.1128\/IAI.73.12.7869-7877.2005","volume":"73","author":"CG Earnhart","year":"2005","unstructured":"Earnhart, C. G., Buckles, E. L., Dumler, J. S. & Marconi, R. T. Demonstration of OspC type diversity in invasive human Lyme disease isolates and identification of previously uncharacterized epitopes that define the specificity of the OspC murine antibody response. Infect. Immun. 73, 7869\u20137877. https:\/\/doi.org\/10.1128\/IAI.73.12.7869-7877.2005 (2005).","journal-title":"Infect. Immun."},{"key":"42941_CR53","doi-asserted-by":"publisher","first-page":"806","DOI":"10.4269\/ajtmh.2008.78.806","volume":"78","author":"DE Dykhuizen","year":"2008","unstructured":"Dykhuizen, D. E. et al. The propensity of different Borrelia burgdorferi sensu stricto genotypes to cause disseminated infections in humans. Am. J. Trop. Med. Hyg. 78, 806\u2013810 (2008).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"42941_CR54","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1086\/314922","volume":"180","author":"GP Wormser","year":"1999","unstructured":"Wormser, G. P. et al. Association of specific subtypes of Borrelia burgdorferi with hematogenous dissemination in early Lyme disease. J. Infect. Dis. 180, 720\u2013725. https:\/\/doi.org\/10.1086\/314922 (1999).","journal-title":"J. Infect. Dis."},{"key":"42941_CR55","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1086\/592279","volume":"198","author":"GP Wormser","year":"2008","unstructured":"Wormser, G. P. et al. Borrelia burgdorferi genotype predicts the capacity for hematogenous dissemination during early Lyme disease. J. Infect. Dis. 198, 1358\u20131364. https:\/\/doi.org\/10.1086\/592279 (2008).","journal-title":"J. Infect. Dis."},{"key":"42941_CR56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0073066","volume":"8","author":"K Hanincova","year":"2013","unstructured":"Hanincova, K. et al. Multilocus sequence typing of Borrelia burgdorferi suggests existence of lineages with differential pathogenic properties in humans. PLoS One 8, e73066. https:\/\/doi.org\/10.1371\/journal.pone.0073066 (2013).","journal-title":"PLoS One"},{"key":"42941_CR57","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1016\/j.ajpath.2011.02.018","volume":"178","author":"K Strle","year":"2011","unstructured":"Strle, K., Jones, K. L., Drouin, E. E., Li, X. & Steere, A. C. Borrelia burgdorferi RST1 (OspC type A) genotype is associated with greater inflammation and more severe Lyme disease. Am. J. Pathol. 178, 2726\u20132739. https:\/\/doi.org\/10.1016\/j.ajpath.2011.02.018 (2011).","journal-title":"Am. J. Pathol."},{"key":"42941_CR58","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1002\/art.24812","volume":"60","author":"KL Jones","year":"2009","unstructured":"Jones, K. L., McHugh, G. A., Glickstein, L. J. & Steere, A. C. Analysis of Borrelia burgdorferi genotypes in patients with Lyme arthritis: High frequency of ribosomal RNA intergenic spacer type 1 strains in antibiotic-refractory arthritis. Arthritis Rheum. 60, 2174\u20132182. https:\/\/doi.org\/10.1002\/art.24812 (2009).","journal-title":"Arthritis Rheum."},{"key":"42941_CR59","doi-asserted-by":"publisher","first-page":"3244","DOI":"10.1128\/AEM.02636-10","volume":"77","author":"NH Ogden","year":"2011","unstructured":"Ogden, N. H. et al. Investigation of genotypes of Borrelia burgdorferi in Ixodes scapularis ticks collected during surveillance in Canada. Appl. Environ. Microbiol. 77, 3244\u20133254. https:\/\/doi.org\/10.1128\/AEM.02636-10 (2011).","journal-title":"Appl. Environ. Microbiol."},{"key":"42941_CR60","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0269266","volume":"17","author":"P Pearson","year":"2022","unstructured":"Pearson, P. et al. A Borrelia burgdorferi outer surface protein C (OspC) genotyping method using Luminex technology. PLoS One 17, e0269266. https:\/\/doi.org\/10.1371\/journal.pone.0269266 (2022).","journal-title":"PLoS One"},{"key":"42941_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.ttbdis.2023.102139","volume":"14","author":"SA Shifflett","year":"2023","unstructured":"Shifflett, S. A. et al. Prevalence of Borrelia burgdorferi and diversity of its outer surface protein C (ospC) alleles in blacklegged ticks (Ixodes scapularis) in Delaware. Ticks Tick Borne Dis 14, 102139. https:\/\/doi.org\/10.1016\/j.ttbdis.2023.102139 (2023).","journal-title":"Ticks Tick Borne Dis"},{"key":"42941_CR62","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010650","volume":"5","author":"CD Crowder","year":"2010","unstructured":"Crowder, C. D. et al. Genotypic variation and mixtures of Lyme Borrelia in Ixodes ticks from North America and Europe. PLoS One 5, e10650. https:\/\/doi.org\/10.1371\/journal.pone.0010650 (2010).","journal-title":"PLoS One"},{"key":"42941_CR63","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.meegid.2014.04.014","volume":"27","author":"SL States","year":"2014","unstructured":"States, S. L. et al. Lyme disease risk not amplified in a species-poor vertebrate community: Similar Borrelia burgdorferi tick infection prevalence and OspC genotype frequencies. Infect Genet Evol 27, 566\u2013575. https:\/\/doi.org\/10.1016\/j.meegid.2014.04.014 (2014).","journal-title":"Infect Genet Evol"},{"key":"42941_CR64","doi-asserted-by":"publisher","DOI":"10.1093\/pnasnexus\/pgad234","volume":"2","author":"MA Combs","year":"2023","unstructured":"Combs, M. A. et al. Host adaptation drives genetic diversity in a vector-borne disease system. PNAS Nexus 2, pgad234. https:\/\/doi.org\/10.1093\/pnasnexus\/pgad234 (2023).","journal-title":"PNAS Nexus"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42941-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42941-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42941-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T23:41:42Z","timestamp":1776987702000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42941-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["42941"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-42941-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"assertion":[{"value":"5 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Marques has a patent US 8,926,989 issued; and is an unpaid Scientific Advisor to the Global Lyme Alliance and to the American Lyme Disease Foundation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13368"}}